Biotech · Private company
PharmaEssentia
Track this companyFree. Adds PharmaEssentia to your Dealase workspace and tells you when its record changes.
Clinical trials99 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- AnagrelidePhase 3 · Essential ThrombocythemiaClinicalTrials.gov · fetched Nov 12, 2026
- P1101 (Ropeginterferon alfa-2b-njft)Phase 3 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- Ropeginterferon alfa-2bPhase 3 · Essential ThrombocythemiaClinicalTrials.gov · fetched Nov 12, 2026
- Ropeginterferon alfa-2bPhase 3 · Primary MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- Ropeginterferon alfa-2b-njft (P1101)Phase 3 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- Ropeginterferon alfa-2b-njft (P1101)Phase 2 · Essential ThrombocythemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaPHASE2 · NOT_YET_RECRUITING · started Jan 30, 2027ClinicalTrials.gov NCT07468916 · fetched Nov 12, 2026
- A Study of Ropeg-Interferon in People With Polycythemia VeraPHASE2 · RECRUITING · started Oct 30, 2026ClinicalTrials.gov NCT07886801 · fetched Nov 12, 2026
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 MutationsPHASE1_PHASE2 · RECRUITING · started Oct 27, 2026ClinicalTrials.gov NCT07646821 · fetched Nov 12, 2026
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisPHASE1 · RECRUITING · started Aug 21, 2026ClinicalTrials.gov NCT07521046 · fetched Nov 12, 2026
- Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)PHASE1 · RECRUITING · started Aug 27, 2025ClinicalTrials.gov NCT07047885 · fetched Nov 12, 2026
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 18, 2025ClinicalTrials.gov NCT06468033 · fetched Nov 12, 2026
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 26, 2022ClinicalTrials.gov NCT05481151 · fetched Nov 12, 2026
- A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 29, 2022ClinicalTrials.gov NCT05482971 · fetched Nov 12, 2026
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntolerancePHASE3 · ACTIVE_NOT_RECRUITING · started Aug 25, 2020ClinicalTrials.gov NCT04285086 · fetched Nov 12, 2026